Loading
NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine and C-DIM 12.
In plain words · NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development.
No product in this corpus aims at NR4A2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA NR4A2: RNA tissue enhanced (adrenal gland 125 nTPM, bone marrow 126 nTPM, ovary 122 nTPM); no normal tissue stained high; highest cancer staining head and neck cancer (3 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas NR4A2 tissue; Open Targets ENSG00000153234 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Mages H.W. et al, Mol. Endocrinol, 1994, "NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3". Source.
Sources: HGNC HGNC:7981 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43354 (protein name, function text, keywords and locations (REST API)); CIViC gene NR4A2 (3 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0))
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons. Location: Cytoplasm; Nucleus (UniProt). Locus 2q24.1 (HGNC).
RNA: tissue enhanced (adrenal gland 125 nTPM, bone marrow 126 nTPM, ovary 122 nTPM), detected in all normal tissues.
No normal tissue stained high.
Medium only: renal cancer, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"NR4A2" OR ABSTRACT:"NR4A2" OR TITLE:"nuclear receptor subfamily 4 group A member 2" OR ABSTRACT:"nuclear receptor subfamily 4 group A member 2" OR TITLE:"Nuclear receptor subfamily 4 group A member 2" OR ABSTRACT:"Nuclear receptor subfamily 4 group A member 2" OR TITLE:"TINUR" OR ABSTRACT:"TINUR" OR TITLE:"RNR1" OR ABSTRACT:"RNR1" OR TITLE:"HZF-3" OR ABSTRACT:"HZF-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NR4A2, not a curated reading list.